EyePoint Pharmaceuticals Inc (PSDV):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:EyePoint Pharmaceuticals Inc (PSDV) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C12134
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. EyePoint’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

EyePoint Pharmaceuticals Inc (PSDV) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
EyePoint Pharmaceuticals Inc, Medical Equipment, Deal Details 11
Partnerships 11
Alimera Sciences Enters into Licensing Agreement with pSivida 11
Enigma Therapeutics Amends Licensing Agreement with pSivida 12
Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 13
Equity Offering 14
EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 14
EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 15
EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 16
EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 17
EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 18
EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 19
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 20
pSivida Raises USD17.8 Million in Public Offering of Shares 21
pSivida Raises USD7 Million in Private Placement of Shares 23
pSivida Announces Private Placement Of Shares For US$19 Million 24
pSivida Completes Public Offering Of Shares For US$10.8 Million 25
pSivida Completes Private Placement Of Units For US$5.4 Million 26
EyePoint Pharmaceuticals Inc – Key Competitors 27
EyePoint Pharmaceuticals Inc – Key Employees 28
EyePoint Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 06, 2018: EyePoint Pharmaceuticals reports fiscal first quarter 2019 financial results and highlights recent clinical and operational developments 30
Sep 12, 2018: EyePoint Pharmaceuticals reports fiscal 2018 fourth quarter & full year financial results and highlights recent progress 32
May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results 35
Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 37
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 38
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 39
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 40
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 41
Feb 07, 2017: pSivida Reports Fiscal 2017 Second Quarter and First Half Results 42
Corporate Communications 44
Nov 27, 2018: EyePoint Pharmaceuticals names Ron Honig, Esq., as SVP, general counsel & company secretary 44
Oct 30, 2018: EyePoint Pharmaceuticals appoints John Landis, Ph.D., M.S., to Board of Directors 45
Sep 10, 2018: EyePoint Pharmaceuticals names Goran Ando as Next Chairman of Board of Directors 46
Aug 15, 2018: Eyepoint Pharmaceuticals appoints John Weet, Ph.D., as SVP, regulatory affairs & quality 47
Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director 48
May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S. 49
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
EyePoint Pharmaceuticals Inc, Medical Equipment, Key Facts, 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 9
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Enters into Licensing Agreement with pSivida 11
Enigma Therapeutics Amends Licensing Agreement with pSivida 12
Ocumension Therapeutics Enters into Licensing Agreement with EyePoint Pharma 13
EyePoint Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 14
EyePoint Pharma Raises USD28.9 Million in Private Placement in Shares upon Exercise of Warrants 15
EyePoint Pharma Plans to Raise Funds through Public Offering of Shares 16
EyePoint Pharma to Raise USD25.5 Million in Private Placement in Second Tranche of Units 17
EyePoint Pharma Raises USD9.5 Million in Private Placement of Securities 18
EyePoint Pharma Raises USD0.5 Million in Private Placement of Securities 19
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 20
pSivida Raises USD17.8 Million in Public Offering of Shares 21
pSivida Raises USD7 Million in Private Placement of Shares 23
pSivida Announces Private Placement Of Shares For US$19 Million 24
pSivida Completes Public Offering Of Shares For US$10.8 Million 25
pSivida Completes Private Placement Of Units For US$5.4 Million 26
EyePoint Pharmaceuticals Inc, Key Competitors 27
EyePoint Pharmaceuticals Inc, Key Employees 28
EyePoint Pharmaceuticals Inc, Subsidiaries 29

List of Figures
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
EyePoint Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[EyePoint Pharmaceuticals Inc (PSDV):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MSIG Holdings (Asia) Pte. Ltd.:企業の戦略・SWOT・財務情報
    MSIG Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MSIG Holdings (Asia) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Australian Gas Networks Ltd-エネルギー分野:企業M&A・提携分析
    Summary Australian Gas Networks Ltd (Australian Gas Networks) formerly Envestra Ltd, is an oil and gas company that distributes and transports natural gas. The company offers services such as managing the haulage of gas through each network, operation and maintenance of gas network, design an constr …
  • Novaliq GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a pres …
  • Daewoong Pharmaceutical Co Ltd (069620):企業の財務・戦略的SWOT分析
    Daewoong Pharmaceutical Co Ltd (069620) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Canadian Tire Corporation, Limited:戦略・SWOT・企業財務分析
    Canadian Tire Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Canadian Tire Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • HTC Corporation:企業の戦略・SWOT・財務情報
    HTC Corporation - Strategy, SWOT and Corporate Finance Report Summary HTC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Kudelski SA (KUD):企業の財務・戦略的SWOT分析
    Kudelski SA (KUD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Sensimed AG-医療機器分野:企業M&A・提携分析
    Summary Sensimed AG (Sensimed) is a medical device company that offers soft contact lens-based solutions. The company’s products comprise Sensimed Triggerfish, a non-invasive soft contact lens-based solution designed for the overall management of glaucoma. It offers automated recording of continuous …
  • High Peak Royalties Limited (HPR)-エネルギー分野:企業M&A・提携分析
    Summary High Peak Royalties Limited (High Peak) is a utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The company has r …
  • Valecha Engineering Ltd:戦略・SWOT・企業財務分析
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Meiji Holdings Co, Ltd.:企業の戦略・SWOT・財務分析
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Lophius Biosciences GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Cadila Healthcare Ltd (CADILAHC):企業の財務・戦略的SWOT分析
    Cadila Healthcare Ltd (CADILAHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • NextEra Energy Resources LLC:企業の戦略的SWOT分析
    NextEra Energy Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • ProteoMediX AG:製品パイプライン分析
    Summary ProteoMediX AG (ProteoMediX) is a medical diagnostic company which identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests for the detection, prognosis, stratification, and therapy-selection …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Avgol Industries 1953 Ltd. (AVGL):企業の財務・戦略的SWOT分析
    Avgol Industries 1953 Ltd. (AVGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ube Industries, Ltd.:企業の戦略・SWOT・財務情報
    Ube Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ube Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mitsui O.S.K. Lines Ltd (9104):石油・ガス:M&Aディール及び事業提携情報
    Summary Mitsui O.S.K. Lines Ltd (MOL) is a global marine logistic company. It owns and operates dry bulkers, tankers, LNG carriers, containerships, ferries & coastal RoRo ships, cruise ships. The company’s dry bulkers transport dry bulk cargo such as iron ore, coal, grains, wood, wood chips, cement, …
  • Vivendi S.A.:戦略・SWOT・企業財務分析
    Vivendi S.A. - Strategy, SWOT and Corporate Finance Report Summary Vivendi S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆